Navigation Links
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease

MIAMI, Jan. 14, 2011 /PRNewswire/ -- New clinical research data suggests that [18F] Flutemetamol could add value to current diagnostic tools used by physicians and provide accurate identification of beta amyloid plaques, considered to be a sign of neurodegeneration linked to Alzheimer's Disease (AD).  Flutemetamol, a GE Healthcare Positron Emission Tomography (PET) imaging agent currently in phase III development, is being studied to identify the uptake of beta amyloid via imaging of the brain tissue in live humans.  Currently, beta amyloid is identified from brain samples acquired post-mortem. Together with other GE Healthcare imaging modalities, this may help physicians detect amyloid deposition and assist in the detection and treatment of AD.

"The wealth of data presented this year at the annual HAI meeting fundamentally supports the value Flutemetamol could bring to the Alzheimer's community," said Jonathan Allis, MI PET Segment Leader, GE Healthcare Medical Diagnostics.  "The ability to make visual assessments of amyloid in AD patients may enable physicians to seek earlier, confirmed diagnosis of AD and make more informed care decisions."

Data highlights from five clinical abstracts from studies of Flutemetamol to be featured at the 5th Annual Human Amyloid Imaging (HAI) meeting in Miami, Florida suggest that:

  • The in vivo PET retention of Flutemetamol and PIB (Pittsburgh Compound B) have comparable patterns of binding;
  • There is a strong concordance between Flutemetamol amyloid imaging and cortical biopsy histopathology using both visual and quantitative methods;
  • The combination of Flutemetamol and structural MRI can provide information that could be useful in understanding other (non-AD) neuro-degenerative diseases and in identifying beta amyloid formation; and
  • Flutemetamol scans can be categorized with automated software suitable for use in clinical practice.

"At GE Healthcare, our scientists and researchers remain fully committed to developing enhanced diagnostics tools that may help Alzheimer's Disease patients and their families get accurate information as early as possible," said Pascale Witz, CEO, GE Healthcare Medical Diagnostics.

GE Healthcare is taking a comprehensive approach to understanding Alzheimer's Disease through its ongoing research to uncover the causes, risks and physical effects of Alzheimer's Disease. The company's global commitment to advance clinical knowledge and provide a variety of technologies to aid the fight in this epidemic may assist physicians in the acceleration of diagnosis and improvement of treatment decisions in all stages of the disease. GE Healthcare already offers a range of imaging modalities used by physicians to assist in the detection of AD and dementia (CT, MRI, PET, SPECT) and has been a key contributor to the Alzheimer's Disease Neuroimaging Initiative since its inception. The company also plays a key role in PredictAD, an EU-funded research project to develop solutions to enable earlier diagnosis of Alzheimer's disease.  [18F] Flutemetamol is only one part of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimer's field.


GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our web site at

For our latest news, please visit

For more information, contact:

Aleisia Gibson
Global PR Manager, GE Healthcare, Medical Diagnostics
(609) 514-6046

SOURCE GE Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. ViroPharma to Present at Three Upcoming Healthcare Conferences
4. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
5. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
6. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
7. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
8. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
9. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10. Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
11. Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... ... CBD College is proud to announce that on November 20th, ... its Diagnostic Medical Sonography program. CBD College is honored to join this very short ... universities in the state of California make the cut. CBD College is officially the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Dr. Thomas ... Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph ... that both STEMI and Sepsis conditions present in similar ways and require time-critical intervention ...
Breaking Medicine News(10 mins):